Pharmaceutical firm Marksans Pharma Ltd shares jumped on Wednesday, June 11, as a block deal estimated at around Rs 250 crore took place on the exchanges.
Around 1.02 crore shares, valued at Rs 257 crore, which represents 2.27 percent of the total outstanding equity, exchanged hands in a block trade at Rs 250 per share.
OrbiMed Asia IV Mauritius FVCI Ltd, a global healthcare investment firm, had initiated a block deal to sell 2.27 percent of its stake in the company, valued at approximately Rs 256.8 crore. The floor price is at Rs 249.95 per share, which is the same as the previous day’s closing price.
At 9.20 am, shares of the firm were quoting Rs 256.5 per share, up 2.7 percent on the NSE
Follow our market blog to catch all the updates
According to the March shareholding details, the promoters of Marksans Pharma hold 43.9 percent equity in the firm, while FIIs and DIIs hold 22.2 percent and 4.6 percent, respectively. The public shareholding in the stock is around 29.4 percent.
Marksans Pharma reported a 15.6 percent year-on-year increase in consolidated net profit for the fourth quarter of FY2025, rising to Rs 90.5 crore from Rs 78.3 crore. Revenue for the quarter grew 26.5 percent to Rs 708.5 crore, compared to Rs 560 crore in the same period last year.
Domestic brokerage HDFC Securities believes that the over-the-counter (OTC) segment in the US is poised for stable demand with minimal price erosion. Considering that Marksans Pharma derives approximately three fourths of its sales from these products, this trend is expected to contribute to a robust margin profile for the drugmaker.
The company's product portfolio is skewed towards over-the-counter segments and soft gel products, which mainly sold in the US and UK markets. The OTC drugs segment is much more stable, when compared to traditional generics formulations that often face concerns over price erosion, which provides a cushion for Marksans Pharma.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
